DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2004/0014109 A1 Pericalk-Vance Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2004/0014109 A1 Pericalk-Vance Et Al US 20040014109A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0014109 A1 Pericalk-Vance et al. (43) Pub. Date: Jan. 22, 2004 (54) METHODS AND GENES ASSOCIATED WITH Related U.S. Application Data SCREENING ASSAYS FOR AGE AT ONSET AND COMMON NEURODEGENERATIVE (60) Provisional application No. 60/382,880, filed on May DISEASES 23, 2002. Provisional application No. 60/396,233, filed on Jul. 16, 2002. Provisional application No. (76) Inventors: Margaret A. Pericak-Vance, Chapel 60/428,876, filed on Nov. 25, 2002. Hill, NC (US); Jeffery M. Vance, Chapel Hill, NC (US); Jonathan L. Publication Classification Haines, Brentwood, TN (US); John Gilbert, Oxford, NC (US); Yi-Ju Li, (51) Int. Cl." ....................................................... C12O 1/68 Durham, NC (US) (52) U.S. Cl. .................................................................. 435/6 Correspondence Address: MYERS BIGELSIBLEY & SAJOVEC (57) ABSTRACT PO BOX 37428 RALEIGH, NC 27627 (US) The present invention discloses methods of Screening a Subject for Alzheimer's disease and/or Parkinson's disease (21) Appl. No.: 10/444,347 comprising detecting the presence or absence of a marker or functional polymorphism associated with a gene linked to (22) Filed: May 23, 2003 Alzheimer's disease and/or Parkinson's disease. Patent Application Publication Jan. 22, 2004 Sheet 1 of 4 US 2004/0014109 A1 OS22 CCS 248 d1 OS 213 OS 230 dOS 237 di Os239 10S677 d1 OS2327 c OS 4.32 s dOS2 C10s,225 OS227 dOs208 d10s A26 d1 OS 1423 2 s di Osal 2 dOS 89 Patent Application Publication Jan. 22, 2004 Sheet 2 of 4 US 2004/0014109 A1 120 D1 OSS 83 DOS677* 30 DOS 239 135 138 150 D OS 230 *Peak marker for multipoint AAO analysis on NIMH dataset. ** Peak marker for multipoint AAO analysis on overall datasets. Figure 2. Overview of chromosome Oq. Patent Application Publication Jan. 22, 2004 Sheet 3 of 4 US 2004/0014109 A1 Figure 3 D10S1239, LOD=2.62 for the D10S1237, LOD=155 combined AD and LOD=2.39 for PD PD datasets for AD SCD NDUFB8 GSTO GSTO2 PRSS Genes - - - sistazart - - 3: - Position O 13 05 102.4 103.4 105.3 115.4 23.5 (MB) - TroT-T-I-T-o-o-o-o-Tre SNP 1 2 3 45 67 89 10 ll-14 Patent Application Publication Jan. 22, 2004 Sheet 4 of 4 US 2004/0014109 A1 - - - Cld NS C r 2. dNS divS Old NS 6d NS 8 NS -sans-39d NS GdNS - tdNS 8 d N S |gS. ds S.I 3d NS sd gl. 2 dNS O' 92 O'C 9 O' 90 O'O US 2004/0014109 A1 Jan. 22, 2004 METHODS AND GENES ASSOCATED WITH develop Signs of parkinsonism, including bradykinesia, SCREENING ASSAYS FOR AGE AT ONSET AND rigidity, and gait abnormalities. Conversely, dementia is a COMMON NEURODEGENERATIVE DISEASES major factor in Parkinson's disease, and the two disorders both exhibit degeneration of cholinergic neurons in the CROSS REFERENCE TO RELATED nucleus basalis of Meynert. Another pathological Similarity APPLICATIONS is the presence of Similar Staining C-Synuclein Lewy bodies (LB) in both disorders, Supporting the premise that the two 0001. The present application claims priority to Provi diseases may share a common pathway leading to LB sional Application No. 60/382,880 filed May 23, 2002, formation (See, Lippa et al., Arch Neurol 58:1817-1820 Provisional Application No. 60/396,233 filed Jul. 16, 2002, (2001)). APOE, a well-proven risk factor for Alzheimier's and Provisional Application No. 60/428,876 filed Nov. 25, disease, has been Suggested to be involved in the risk for 2002, the disclosures of which are hereby incorporated by Parkinson's disease as well, although others have failed to reference in their entireties. confirm these findings. Khan et al., Ann Neurol 49:665-668 (2001). The taugene, a major element in the neurofibulary STATEMENT OF FEDERAL SUPPORT tangles of Alzheimer's disease, has recently been shown to 0002 This invention was made with support from the be associated with Parkinson's disease as well (See, Martin United States Federal government under grant numbers R01 et al.). These similarities are likely not derived from the NS31153, P50 NS39764, P01 NS26630, NS31153, biologic events that initiate the Start of each disease but AG05128, AG13308, AG11268, AG10123, AG19085, rather from overlapping neuropathic pathways involved in MH52453 and MH59528 from the National Institutes of the progression of each disorder. Health. The United States Government has certain rights in 0006 Several recent reports have focused attention on this invention. chromosome 10q for Alzheimer's disease, (Bertram et al., Science 290:2302-2305 (2000); Ertekin-Taner et al., Science FIELD OF THE INVENTION 290:2303-2304 (2000); Myers et al., Science 290:2304-2305 0003. This invention concerns methods of screening for (2000); Pericak-Vance) but have been inconsistent in local Alzheimer's disease and/or Parkinson's disease by the ization (FIG. 2). Only the region identified by Bertram et al. Screening of genetic risk factors. (2000) by use of the NIMH family-sample data set maps near the present region. FIG. 2 depicts the map positions of BACKGROUND OF THE INVENTION published linkage regions for risk genes on chromosome 10q and the present linkage Findings for AAO genes. The 0004 Genetic studies of common complex neurodegen linkage effect on chromosome 10q spans the different data erative diseases, Such as Alzheimer's disease and Parkin Sets used in the analyses. Three independent risk-gene Son's disease, have focused on the identification of risk studies (Ertekin-Taner et al.; Myers et al.; and Pericak-Vance genes as targets for development of new treatments and et al.) identified an overlapping region (between D10S1225 improved diagnoses. This approach has identified the amy and D10S1211) that is ~47 cM proximal to the present loid precursor protein (APP) (Goate et al., Nature 349:704 linkage region for AAO. For Parkinson's disease, no risk 706 (1991)), presenilin 1 (PS1) (Sherrington et al., Nature genes have yet been reported on chromosome 10. See, Scott 375:754-760 (1995)), presenilin 2 (PS2) (Levy-Lahad et al., et al. 2001. Science 269:973-977 (1995); Rogaev et al., Nature 376:775 778 (1995)), and apolipoprotein E (APOE) (Corder et al., 0007 GSTO1 (or called GSTO1-1) is a member of the Science 261:921-923 (1993)) genes as contributing to risk in glutathione S-transferase (GST) family of genes that utilize Alzheimer's disease. APP, PS1, and PS2 cause rare early glutathione in reactions and contribute to the biotransfor onset autosomal dominant Alzheimer's disease (5% of mation and disposition of many compounds, including Alzheimer's disease cases), whereas APOE is associated drugs, carcinogens, and the products of oxidative StreSS. with both risk and age at onset (AAO) in late-onset familial GSTO1 is known to be expressed in a wide range of tissues, Alzheimer's disease, as well as in late- and early-onset specifically neural glial cells Board et al., J Biol. Chem. 275, Sporadic Alzheimer's disease. Similarly, three genes have 24798 (2000). GSTO1 is unusual in that it has a different been identified to associate with risk in Parkinson's disease: substrate profile than other members of this family, notably C-synuclein (Polymeropoulos et al., Science 274:1197–1199 a glutathione dependent thiotransferase activity Similar to (1996)) for rare autosomal dominant early-onset Parkinson's glutaredoxins. In addition, Dulhunty et al. have reported that disease, Parkin (Abbas et al., Hum Mol Genet 8:567-574 in cells containing ryanodine receptors it may have a role in (1999)) for rare autosomal recessive juvenile parkinsonism protecting from calcium-induced apotosis. J. Biol. Chem. and autosomal recessive early-onset Parkinson's disease, 276,3319 (2001). Zakharyan et al. have implicated it in the and tau (Martin et al., JAMA 286:224.5-2250 (2001)) for biotransformation of inorganic arsenic as well. Chem. ReS. classic Parkinson's disease. Genomic Screens in both Par Toxicol. 14, 1051 (2001). kinson's disease (Destefano et al., Neurology 57:1124-1126 0008 Identification of further genes would open new (2001); Scott et al., JAMA 286:2239-2244 (2001)) and avenues of research with the potential to delay onset beyond Alzheimer's disease (Kehoe et al., Hum Mol Genet 8:237 the natural life span. Present knowledge about genes con 245 (1999); Pericak-Vance et al., Exp Gerontol 35:1343 tributing to AAO in neurodegenerative diseases clearly lags 1352 (2000) have recently localized additional but, as yet, behind the understanding of genes contributing to risk. unknown risk genes. Recently, there has been growing interest in using AAO 0005 Both Alzheimier's disease and Parkinson's disease information as a quantitative trait, to identify genes that are neurodegenerative, late-AAO disorders. Clinically, a influence onset of disease (Daw et al., Am J Hum Genet Significant number of patients with Alzheimer's disease 64:839-851 (1999), Daw et al., Am J Hum Genet 66:196-204 US 2004/0014109 A1 Jan. 22, 2004 (2000); Duggirala et al. Am J Hum Genet 64:1127-1140 DETAILED DESCRIPTION OF THE (1999)). Rapid development of methods of mapping quan EMBODIMENTS titative trait loci (QTLS) for general pedigrees (Goldgar, Am J Hum Genet 47.957-967 (1990); Amos, Am J Hum Genet 0016. As noted above, the present invention provides a 54:535-543 (1994); Blangero et al. Genet Epidemiol 14:959 method of Screening (e.g., diagnosing, detecting, determin 964 (1997)) has now made the search for novel genes ing or prognosing) for Alzheimer's disease and/or Parkin affecting AAO feasible. Nevertheless, the genetic basis for Son's disease in a Subject.
Load more

Recommended publications
  • Supplementary Data
    Figure 2S 4 7 A - C 080125 CSCs 080418 CSCs - + IFN-a 48 h + IFN-a 48 h + IFN-a 72 h 6 + IFN-a 72 h 3 5 MRFI 4 2 3 2 1 1 0 0 MHC I MHC II MICA MICB ULBP-1 ULBP-2 ULBP-3 ULBP-4 MHC I MHC II MICA MICB ULBP-1 ULBP-2 ULBP-3 ULBP-4 7 B 13 080125 FBS - D 080418 FBS - + IFN-a 48 h 12 + IFN-a 48 h + IFN-a 72 h + IFN-a 72 h 6 080125 FBS 11 10 5 9 8 4 7 6 3 MRFI 5 4 2 3 2 1 1 0 0 MHC I MHC II MICA MICB ULBP-1 ULBP-2 ULBP-3 ULBP-4 MHC I MHC II MICA MICB ULBP-1 ULBP-2 ULBP-3 ULBP-4 Molecule Molecule FIGURE 4S FIGURE 5S Panel A Panel B FIGURE 6S A B C D Supplemental Results Table 1S. Modulation by IFN-α of APM in GBM CSC and FBS tumor cell lines. Molecule * Cell line IFN-α‡ HLA β2-m# HLA LMP TAP1 TAP2 class II A A HC§ 2 7 10 080125 CSCs - 1∞ (1) 3 (65) 2 (91) 1 (2) 6 (47) 2 (61) 1 (3) 1 (2) 1 (3) + 2 (81) 11 (80) 13 (99) 1 (3) 8 (88) 4 (91) 1 (2) 1 (3) 2 (68) 080125 FBS - 2 (81) 4 (63) 4 (83) 1 (3) 6 (80) 3 (67) 2 (86) 1 (3) 2 (75) + 2 (99) 14 (90) 7 (97) 5 (75) 7 (100) 6 (98) 2 (90) 1 (4) 3 (87) 080418 CSCs - 2 (51) 1 (1) 1 (3) 2 (47) 2 (83) 2 (54) 1 (4) 1 (2) 1 (3) + 2 (81) 3 (76) 5 (75) 2 (50) 2 (83) 3 (71) 1 (3) 2 (87) 1 (2) 080418 FBS - 1 (3) 3 (70) 2 (88) 1 (4) 3 (87) 2 (76) 1 (3) 1 (3) 1 (2) + 2 (78) 7 (98) 5 (99) 2 (94) 5 (100) 3 (100) 1 (4) 2 (100) 1 (2) 070104 CSCs - 1 (2) 1 (3) 1 (3) 2 (78) 1 (3) 1 (2) 1 (3) 1 (3) 1 (2) + 2 (98) 8 (100) 10 (88) 4 (89) 3 (98) 3 (94) 1 (4) 2 (86) 2 (79) * expression of APM molecules was evaluated by intracellular staining and cytofluorimetric analysis; ‡ cells were treatead or not (+/-) for 72 h with 1000 IU/ml of IFN-α; # β-2 microglobulin; § β-2 microglobulin-free HLA-A heavy chain; ∞ values are indicated as ratio between the mean of fluorescence intensity of cells stained with the selected mAb and that of the negative control; bold values indicate significant MRFI (≥ 2).
    [Show full text]
  • Molecular Study of Malignant Gliomas Treated
    Cancer Therapy: Clinical Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01 Andrew B. Lassman,1MichaelR.Rossi,5 Jeffrey R. Razier,6 Lauren E. Abrey,1FrankS. Lieberman, 7 Chelsea N. Grefe,2 Kathleen Lamborn,8 William Pao,2,3 Alan H. Shih,2 John G. Kuhn,9 Richard Wilson,10 Norma J. Nowak, 5 John K. Cowell,5 Lisa M. DeAngelis,1 PatrickWen, 11 MarkR. Gilbert, 12 Susan Chang,8 W.A.Yung,12 Michael Prados,8 and Eric C. Holland1,2,4 Abstract Purpose: We investigated the molecular effect of the epidermal growth factor receptor (EGFR) inhibitors erlotinib and gefitinib in vivo on all available tumors from patients treated on North American BrainTumor Consortium trials 01-03 and 00-01for recurrent or progressive malignant glioma. Experimental Design: EGFRexpression and signaling during treatment with erlotinib or gefitinib were analyzed by Western blot and compared with pre ^ erlotinib/gefitinib ^ exposed tissue or unexposed controls.Tumors were also analyzed for EGFR mutations and for other genomic abnor- malities by array-based comparative genomic hybridization. Clinical data were used to associate molecular features with tumor sensitivity to erlotinib or gefitinib. Results: Erlotinib and gefitinib did not markedly affect EGFR activity in vivo.Nolungsignature mutations of EGFR exons 18 to 21were observed.There was no clear association between erloti- nib/gefitinib sensitivity and deletion or amplification events on array-based comparative genomic hybridization analysis, although novel genomic changes were identified. Conclusions: As erlotinib and gefitinib were generally ineffective at markedly inhibiting EGFR phosphorylation in these tumors, other assays may be needed to detect molecular effects.
    [Show full text]
  • Glutathione S-Transferase Omega Genes in Alzheimer and Parkinson
    Allen et al. Molecular Neurodegeneration 2012, 7:13 http://www.molecularneurodegeneration.com/content/7/1/13 RESEARCHARTICLE Open Access Glutathione S-transferase omega genes in Alzheimer and Parkinson disease risk, age-at- diagnosis and brain gene expression: an association study with mechanistic implications Mariet Allen1, Fanggeng Zou1, High Seng Chai2, Curtis S Younkin1, Richard Miles1, Asha A Nair2, Julia E Crook3, V Shane Pankratz2, Minerva M Carrasquillo1, Christopher N Rowley1, Thuy Nguyen1,LiMa1, Kimberly G Malphrus1, Gina Bisceglio1, Alexandra I Ortolaza1, Ryan Palusak1, Sumit Middha2, Sooraj Maharjan2, Constantin Georgescu1, Debra Schultz4, Fariborz Rakhshan4, Christopher P Kolbert4, Jin Jen4, Sigrid B Sando5,6, Jan O Aasly5,6, Maria Barcikowska7, Ryan J Uitti8, Zbigniew K Wszolek8, Owen A Ross1, Ronald C Petersen9, Neill R Graff-Radford8, Dennis W Dickson1, Steven G Younkin1 and Nilüfer Ertekin-Taner1,8* Abstract Background: Glutathione S-transferase omega-1 and 2 genes (GSTO1, GSTO2), residing within an Alzheimer and Parkinson disease (AD and PD) linkage region, have diverse functions including mitigation of oxidative stress and may underlie the pathophysiology of both diseases. GSTO polymorphisms were previously reported to associate with risk and age-at-onset of these diseases, although inconsistent follow-up study designs make interpretation of results difficult. We assessed two previously reported SNPs, GSTO1 rs4925 and GSTO2 rs156697, in AD (3,493 ADs vs. 4,617 controls) and PD (678 PDs vs. 712 controls) for association with disease risk (case-controls), age-at-diagnosis (cases) and brain gene expression levels (autopsied subjects). Results: We found that rs156697 minor allele associates with significantly increased risk (odds ratio = 1.14, p = 0.038) in the older ADs with age-at-diagnosis > 80 years.
    [Show full text]
  • Lomas Ukbicgcmetatext.Final
    Edinburgh Research Explorer Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations Citation for published version: SpiroMeta Consortium, Int COPD Genetics Consortium & Understanding Soc Sci Grp 2019, 'Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations', Nature Genetics, vol. 51, no. 3, pp. 494-+. https://doi.org/10.1038/s41588-018-0342-2 Digital Object Identifier (DOI): 10.1038/s41588-018-0342-2 Link: Link to publication record in Edinburgh Research Explorer Document Version: Peer reviewed version Published In: Nature Genetics General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 29. Sep. 2021 Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell type and phenotype associations Phuwanat Sakornsakolpat1,2,51, Dmitry Prokopenko1,3,51, Maxime Lamontagne4, Nicola F. Reeve5, Anna L. Guyatt5, Victoria E. Jackson5, Nick Shrine5, Dandi Qiao1, Traci M. Bartz6,7,8, Deog Kyeom Kim9, Mi Kyeong Lee10, Jeanne C. Latourelle11, Xingnan Li12, Jarrett D. Morrow1, Ma'en Obeidat13, Annah B. Wyss10, Per Bakke14, R Graham Barr15, Terri H.
    [Show full text]
  • Signatures of Adaptive Evolution in Platyrrhine Primate Genomes 5 6 Hazel Byrne*, Timothy H
    1 2 Supplementary Materials for 3 4 Signatures of adaptive evolution in platyrrhine primate genomes 5 6 Hazel Byrne*, Timothy H. Webster, Sarah F. Brosnan, Patrícia Izar, Jessica W. Lynch 7 *Corresponding author. Email [email protected] 8 9 10 This PDF file includes: 11 Section 1: Extended methods & results: Robust capuchin reference genome 12 Section 2: Extended methods & results: Signatures of selection in platyrrhine genomes 13 Section 3: Extended results: Robust capuchins (Sapajus; H1) positive selection results 14 Section 4: Extended results: Gracile capuchins (Cebus; H2) positive selection results 15 Section 5: Extended results: Ancestral Cebinae (H3) positive selection results 16 Section 6: Extended results: Across-capuchins (H3a) positive selection results 17 Section 7: Extended results: Ancestral Cebidae (H4) positive selection results 18 Section 8: Extended results: Squirrel monkeys (Saimiri; H5) positive selection results 19 Figs. S1 to S3 20 Tables S1–S3, S5–S7, S10, and S23 21 References (94 to 172) 22 23 Other Supplementary Materials for this manuscript include the following: 24 Tables S4, S8, S9, S11–S22, and S24–S44 1 25 1) Extended methods & results: Robust capuchin reference genome 26 1.1 Genome assembly: versions and accessions 27 The version of the genome assembly used in this study, Sape_Mango_1.0, was uploaded to a 28 Zenodo repository (see data availability). An assembly (Sape_Mango_1.1) with minor 29 modifications including the removal of two short scaffolds and the addition of the mitochondrial 30 genome assembly was uploaded to NCBI under the accession JAGHVQ. The BioProject and 31 BioSample NCBI accessions for this project and sample (Mango) are PRJNA717806 and 32 SAMN18511585.
    [Show full text]
  • A Personalized Genomics Approach of the Prostate Cancer
    cells Article A Personalized Genomics Approach of the Prostate Cancer Sanda Iacobas 1 and Dumitru A. Iacobas 2,* 1 Department of Pathology, New York Medical College, Valhalla, NY 10595, USA; [email protected] 2 Personalized Genomics Laboratory, Center for Computational Systems Biology, Roy G Perry College of Engineering, Prairie View A&M University, Prairie View, TX 77446, USA * Correspondence: [email protected]; Tel.: +1-936-261-9926 Abstract: Decades of research identified genomic similarities among prostate cancer patients and proposed general solutions for diagnostic and treatments. However, each human is a dynamic unique with never repeatable transcriptomic topology and no gene therapy is good for everybody. Therefore, we propose the Genomic Fabric Paradigm (GFP) as a personalized alternative to the biomarkers approach. Here, GFP is applied to three (one primary—“A”, and two secondary—“B” & “C”) cancer nodules and the surrounding normal tissue (“N”) from a surgically removed prostate tumor. GFP proved for the first time that, in addition to the expression levels, cancer alters also the cellular control of the gene expression fluctuations and remodels their networking. Substantial differences among the profiled regions were found in the pathways of P53-signaling, apoptosis, prostate cancer, block of differentiation, evading apoptosis, immortality, insensitivity to anti-growth signals, proliferation, resistance to chemotherapy, and sustained angiogenesis. ENTPD2, AP5M1 BAIAP2L1, and TOR1A were identified as the master regulators of the “A”, “B”, “C”, and “N” regions, and potential consequences of ENTPD2 manipulation were analyzed. The study shows that GFP can fully characterize the transcriptomic complexity of a heterogeneous prostate tumor and identify the most influential genes in each cancer nodule.
    [Show full text]
  • Expanded Genomewide Scan Implicates a Novel Locus at 3Q28 Among Caribbean Hispanics with Familial Alzheimer Disease
    ORIGINAL CONTRIBUTION Expanded Genomewide Scan Implicates a Novel Locus at 3q28 Among Caribbean Hispanics With Familial Alzheimer Disease Joseph H. Lee, DrPH; Rong Cheng, PhD; Vincent Santana, MBA; Jennifer Williamson, MS; Rafael Lantigua, MD; Martin Medrano, MD; Alex Arriaga, MD; Yaakov Stern, PhD; Benjamin Tycko, MD, PhD; Ekaterina Rogaeva, PhD; Yosuke Wakutani, PhD; Toshitaka Kawarai, MD; Peter St George–Hyslop, MD; Richard Mayeux, MD, MSc Objectives: To identify novel candidate regions for late- of .03 (logarithm of odds [LOD], 3.09) in a dominant model onset Alzheimer disease (LOAD) and to confirm link- for probable and possible LOAD. Other regions sugges- age in previously identified chromosomal regions. tive of linkage included 2p25.3 (LOD, 1.77), 7p21.1 (LOD, 1.82), and 9q32 (LOD, 1.94). Under a recessive model, Design: Family-based linkage analysis. we also identified loci at 5p15.33 (LOD, 1.86), 12q24.21 Setting: Probands with familial LOAD identified in clin- (LOD, 2.43), 14q22.3 (LOD, 2.53), and 14q23.1 (LOD, ics in the Dominican Republic, Puerto Rico, and the 2.16) as suggestive for linkage. Restricted to probable United States. LOAD, many of these loci continued to meet criteria sug- gestive for linkage, as did loci at 2p25.3 (LOD, 2.72), 3q28 Patients: We conducted a genome scan in 1161 mem- (LOD, 2.28), 6p21.31 (LOD, 2.19), and 7p21.1 (LOD, bers primarily clinically diagnosed as having LOAD; these 2.05). APOE conditional analysis indicated that the ob- members were from 209 families of Caribbean Hispanic served linkage at 3q28 was independent of the APOE ε4 ancestry.
    [Show full text]
  • Comparative Genomics Reveals Contraction in Cytosolic
    bioRxiv preprint doi: https://doi.org/10.1101/485615; this version posted December 4, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Comparative genomics reveals contraction in cytosolic glutathione transferase genes in cetaceans: implications for oxidative stress adaptation Ran Tian, Inge Seim, Wenhua Ren, Shixia Xu*, Guang Yang* Jiangsu Key Laboratory for Biodiversity and Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing, China *Corresponding author: E-mail: [email protected]; [email protected]. Abstract Cetaceans, a highly specialized group of aquatic mammals, experience oxidative stress induced by reactive oxygen species (ROS) production associated with the apnea/reoxygenation. The glutathione transferases (GST) family possesses multiple functions in detoxification and antioxidant defenses. However, the molecular evolution of GST family in cetaceans is still poorly investigated. Here, we characterized the GST gene family across 21 mammalian genomes including cetaceans and terrestrial relatives. Overall, 7 GST classes were identified, showing GSTs are ubiquitous and conservative to all mammals. Some of GSTs are lineage- specific duplication and loss, in line with a birth-and-death evolutionary model. We detected positive selection sites that possibly influence GST structure and function, suggesting adaptive evolution of GSTs is important for defending mammals from various types of noxious environmental compounds. There is evidence for loss of alpha and mu GST class in cetacean lineages when compared to their terrestrial relatives, consisting with the lower GST activities observed in cetaceans.
    [Show full text]
  • Toward Understanding the Genetic Basis of Adaptation to High
    UC Berkeley UC Berkeley Previously Published Works Title Toward understanding the genetic basis of adaptation to high-elevation life in poikilothermic species: A comparative transcriptomic analysis of two ranid frogs, Rana chensinensis and R. kukunoris Permalink https://escholarship.org/uc/item/4x27k517 Journal BMC Genomics, 13(1) ISSN 1471-2164 Authors Yang, Weizhao Qi, Yin Bi, Ke et al. Publication Date 2012-11-01 DOI http://dx.doi.org/10.1186/1471-2164-13-588 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Yang et al. BMC Genomics 2012, 13:588 http://www.biomedcentral.com/1471-2164/13/588 RESEARCH ARTICLE Open Access Toward understanding the genetic basis of adaptation to high-elevation life in poikilothermic species: A comparative transcriptomic analysis of two ranid frogs, Rana chensinensis and R. kukunoris Weizhao Yang1,2, Yin Qi1,KeBi3 and Jinzhong Fu1,4* Abstract Background: Understanding how organisms adapt to high-elevation environments at a genome scale provides novel insights into the process of adaptive evolution. Previous studies have mainly focused on endothermic organisms, while poikilothermic species may have evolved different mechanisms to cope with high-elevation environments. In this context, we sequenced transcriptomes of a pair of closely related anuran species, Rana chensinensis and R. kukunoris, which inhabit respective low- and high-elevation habitats. By comparing the two transcriptomes, we identified candidate genes that may be involved in high-elevation adaption in poikilothermic species. Results: Over 66 million sequence reads from each transcriptome were generated. A total of 41,858 and 39,293 transcripts for each species were obtained by de novo assembly.
    [Show full text]
  • Ancient Origin of the New Developmental Superfamily DANGER Nikolas Nikolaidis1.*, Dimitra Chalkia1., D
    Ancient Origin of the New Developmental Superfamily DANGER Nikolas Nikolaidis1.*, Dimitra Chalkia1., D. Neil Watkins2, Roxanne K. Barrow3, Solomon H. Snyder3,4,5, Damian B. van Rossum1, Randen L. Patterson1* 1 Biology Department, Pennsylvania State University, University Park, Pennsylvania, United States of America, 2 The Sidney Kimmel Cancer Institute, Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States of America, 3 The Solomon H. Snyder Department of Neuroscience, Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States of America, 4 Department of Pharmacology and Molecular Science, Johns Hopkins University, Baltimore, Maryland, United States of America, 5 Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, Maryland, United States of America Developmental proteins play a pivotal role in the origin of animal complexity and diversity. We report here the identification of a highly divergent developmental protein superfamily (DANGER), which originated before the emergence of animals (,850 million years ago) and experienced major expansion-contraction events during metazoan evolution. Sequence analysis demonstrates that DANGER proteins diverged via multiple mechanisms, including amino acid substitution, intron gain and/or loss, and recombination. Divergence for DANGER proteins is substantially greater than for the prototypic member of the superfamily (Mab-21 family) and other developmental protein families (e.g., WNT proteins). DANGER proteins are widely expressed and display species-dependent tissue expression patterns, with many members having roles in development. DANGER1A, which regulates the inositol trisphosphate receptor, promotes the differentiation and outgrowth of neuronal processes. Regulation of development may be a universal function of DANGER family members. This family provides a model system to investigate how rapid protein divergence contributes to morphological complexity.
    [Show full text]
  • Association Between Arsenic Metabolism Gene Polymorphisms
    www.nature.com/scientificreports OPEN Association between arsenic metabolism gene polymorphisms and arsenic-induced skin lesions in Received: 8 May 2017 Accepted: 19 December 2017 individuals exposed to high-dose Published: xx xx xxxx inorganic arsenic in northwest China Lanrong Luo1, Yuanyuan Li1, Yanhui Gao1, Lijun Zhao1, Hongqi Feng1, Wei Wei1, Chuanying Qiu2, Qian He1, Yanting Zhang1, Songbo Fu1 & Dianjun Sun1 Individuals in a given environment contaminated with arsenic have diferent susceptibilities to disease, which may be related to arsenic metabolism, age, gender, genetics and other factors. This study recruited 850 subjects, including 331 cases and 519 controls, from populations exposed to high levels of arsenic in drinking water in northwest China. Genotypes were determined using a custom- by-design 48-Plex SNPscanTM kit. The results indicated that subjects who carried at least one C allele for GSTO1 rs11191979 polymorphism, at least one A allele for GSTO1 rs2164624, at least one A allele for GSTO1 rs4925, the AG genotype for GSTO2 rs156697, the AG genotype or at least one G allele for GSTO2 rs2297235 or the GG genotype or at least one G allele for PNP rs3790064 had an increased risk of arsenic-related skin lesions. In addition, the haplotype CT between rs4925 and rs11191979 appeared to confer a high risk of arsenic-included skin lesions (OR = 1.377, 95% CI = 1.03–1.84), as did the haplotype GCG among rs156697, rs157077 and rs2297235 (OR = 2.197, 95% CI = 1.08–4.44). The results showed that the variants of GSTO1, GSTO2 and PNP render the susceptible toward developing arsenic-induced skin lesions in individuals exposed to high-dose inorganic arsenic in northwest China.
    [Show full text]
  • Genetic Variants Associated with the Risk of Chronic Obstructive Pulmonary Disease with and Without Lung Cancer
    Published OnlineFirst November 1, 2011; DOI: 10.1158/1940-6207.CAPR-11-0243 Cancer Prevention Research Article Research Genetic Variants Associated with the Risk of Chronic Obstructive Pulmonary Disease with and without Lung Cancer Mariza de Andrade2, Yan Li1,8, Randolph S. Marks3, Claude Deschamps7, Paul D. Scanlon4, Curtis L. Olswold2, Ruoxiang Jiang2, Stephen J. Swensen5, Zhifu Sun2, Julie M. Cunningham6, Jason A. Wampfler2, Andrew H. Limper4, David E. Midthun4, and Ping Yang1 Abstract Chronic obstructive pulmonary disease (COPD) is a strong risk factor for lung cancer. Published studies about variations of genes encoding glutathione metabolism, DNA repair, and inflammatory response pathways in susceptibility to COPD were inconclusive. We evaluated 470 single-nucleotide polymorphisms (SNP) from 56 genes of these three pathways in 620 cases and 893 controls to identify susceptibility markers for COPD risk, using existing resources. We assessed SNP- and gene-level effects adjusting for sex, age, and smoking status. Differential genetic effects on disease risk with and without lung cancer were also assessed; cumulative risk models were established. Twenty-one SNPs were found to be significantly associated with risk of COPD (P < 0.01); gene-based analyses confirmed two genes (GCLC and GSS) and identified three additional genes (GSTO2, ERCC1, and RRM1). Carrying 12 high-risk alleles may increase risk by 2.7-fold; eight SNPs altered COPD risk without lung cancer by 3.1-fold and 4 SNPs altered the risk with lung cancer by 2.3-fold. Our findings indicate that multiple genetic variations in the three selected pathways contribute to COPD risk through GCLC, GSS, GSTO2, ERCC1, and RRM1 genes.
    [Show full text]